Investigation of the effects of the chronic administration of some antihypertensive drugs on enzymatic and non-enzymatic oxidant/antioxidant parameters in rat ovarian tissue

Salman S., Kumbasar S., Yilmaz M., KUMTEPE Y., BÖREKÇİ B., Bakan E., ...Daha Fazla

Gynecological Endocrinology, cilt.27, sa.11, ss.895-899, 2011 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 11
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3109/09513590.2010.551564
  • Dergi Adı: Gynecological Endocrinology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.895-899
  • Anahtar Kelimeler: antihypertensive, Ovary, oxidant/antioxidant parameters, rat
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Hayır

Özet

Objective.In this study, effects of chronic antihypertensive drug (clonidine, methyldopa, amlodipine, ramipril, and rilmenidine) treatment on antioxidantoxidant parameters were investigated in rat ovarian tissue. Study design.Chronic drug administration for 30 days and at the end, biochemical examinations (total glutathione (tGSH), glutathione peroxidase (GPO), glutathione reductase (GR), glutathione s-transferase (GST), superoxide dismutase (SOD), nitric oxide (NO), catalase (CAT), malondialdehyde (MDA), and myeloperoxidase (MPO) analyses) were performed. Results.The levels of glutathione (GSH) and NO, and the activities of GPO, GR, GST, SOD, and CAT were measured the lowest in ramiprile group. Also in ramiprile group, the level of MDA and the activity of MPO was the highest. Conclusion.We divided the drugs into four groups according to their biochemical side effect potentials in ovarian tissue: (I) Drugs which have no clear negative effect on ovarian tissue: clonidine, rilmenidine; (II) Drugs which have mild negative effect on ovarian tissue: methyldopa; (III) Drugs which have moderate negative effect on ovarian tissue: amlodipine; (IV) Drugs which have severe negative effect on ovarian tissue: ramipril. These data might be useful in the selection of the least toxic antihypertensive drug in pregnant and/or normal females. © 2011 Informa UK, Ltd.